KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (2016 - 2025)

Nektar Therapeutics (NKTR) has 13 years of Shares Outstanding data on record, last reported at $187.4 million in Q2 2022.

  • For Q2 2022, Shares Outstanding rose 1.98% year-over-year to $187.4 million; the TTM value through Jun 2022 reached $187.4 million, up 1.98%, while the annual FY2021 figure was $185.5 million, 2.99% up from the prior year.
  • Shares Outstanding reached $187.4 million in Q2 2022 per NKTR's latest filing, up from $186.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $187.4 million in Q2 2022 and bottomed at $162.4 million in Q1 2018.
  • Average Shares Outstanding over 5 years is $178.3 million, with a median of $178.3 million recorded in 2020.
  • Peak YoY movement for Shares Outstanding: grew 8.78% in 2018, then increased 1.48% in 2019.
  • A 5-year view of Shares Outstanding shows it stood at $173.5 million in 2018, then grew by 1.71% to $176.5 million in 2019, then increased by 2.03% to $180.1 million in 2020, then grew by 2.99% to $185.5 million in 2021, then increased by 1.04% to $187.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $187.4 million in Q2 2022, $186.3 million in Q1 2022, and $185.5 million in Q4 2021.